Literature DB >> 21879266

Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.

Ho Min Kim1, Naotsugu Haraguchi, Hideshi Ishii, Masahisa Ohkuma, Miho Okano, Koshi Mimori, Hidetoshi Eguchi, Hirofumi Yamamoto, Hiroaki Nagano, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori.   

Abstract

BACKGROUND: Recently, it has been reported that a small population of cancer stem cells (CSCs) play a role in resistance to chemotherapy and radiation therapy. We reported that CD13(+) liver CSCs survive in hypoxic lesions after chemotherapy, presumably through increased expression of CD13/Aminopeptidase N, which is a scavenger enzyme in the reactive oxygen species (ROS) metabolic pathway. On the other hand, the concept of epithelial-mesenchymal transition (EMT) was indicated by a recent study showing an increased plasticity linked to the cellular "stemness" of CSCs.
METHODS: To study the relationship between CSCs and EMT, we examined biological characteristics of liver cancer cell lines with EMT by exposing transforming growth factor-β (TGF-β).
RESULTS: We showed that a TGF-β-induced EMT-like phenomenon is associated with increased CD13 expression in liver cancer cells. This phenomenon prevents further increases in the ROS level as well as the induction of apoptosis, promoting the survival of CD13(+) CSCs, whereas inhibition of CD13 stimulates apoptosis. Immunohistochemical analysis also indicated that after chemotherapy, CD13 was coexpressed with N-cadherin in surviving cancer cells within fibrous capsules. We have demonstrated that CD13 expression plays a role in supporting the survival of CSCs and that there is an EMT-associated reduction in ROS elevation.
CONCLUSIONS: This novel and consistent linkage between functional CSC markers and the EMT phenomenon suggests a bona fide candidate for targeted therapy for EMT-mediated invasion and metastasis of liver cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879266     DOI: 10.1245/s10434-011-2040-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  55 in total

1.  pIgR: frenemy of inflammation, EMT, and HCC progression.

Authors:  Nathalie Sphyris; Sendurai A Mani
Journal:  J Natl Cancer Inst       Date:  2011-10-24       Impact factor: 13.506

2.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 3.  Reactive oxygen species in cancer stem cells.

Authors:  Xiaoke Shi; Yan Zhang; Junheng Zheng; Jingxuan Pan
Journal:  Antioxid Redox Signal       Date:  2012-03-09       Impact factor: 8.401

Review 4.  Roles of mitochondria in liver cancer stem cells.

Authors:  Ching-Wen Chang; Jeng-Fan Lo; Xin Wei Wang
Journal:  Differentiation       Date:  2019-05-30       Impact factor: 3.880

Review 5.  Clinical and Biological Implications of Cancer Stem Cells in Hepatocellular Carcinoma.

Authors:  Hiroyuki Tsuchiya; Goshi Shiota
Journal:  Yonago Acta Med       Date:  2021-01-06       Impact factor: 1.641

6.  Effects of shear stresses and antioxidant concentrations on the production of reactive oxygen species in lung cancer cells.

Authors:  Kai-Yin Lo; Yun Zhu; Hsieh-Fu Tsai; Yung-Shin Sun
Journal:  Biomicrofluidics       Date:  2013-11-26       Impact factor: 2.800

7.  Evidence for and against epithelial-to-mesenchymal transition in the liver.

Authors:  Guanhua Xie; Anna Mae Diehl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-24       Impact factor: 4.052

Review 8.  Role of liver stem cells in hepatocarcinogenesis.

Authors:  Lei-Bo Xu; Chao Liu
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

Review 9.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

10.  Genotoxic therapy stimulates error-prone DNA repair in dormant hepatocellular cancer stem cells.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-03-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.